AMAG Pharmaceuticals has a diverse portfolio of products in the areas of maternal health, anemia management and cancer supportive care. The company was founded in 1981 and is based in Waltham, Massachusetts.
AMAG Pharmaceuticals, Inc. (AMAG) today announced that management will participate at the Jefferies Virtual Global Healthcare Conference on Wednesday, June 3, 2020 at 4:00 p.m. Eastern Time. A live audio webcast of the virtual event will be accessible through the Investors section of the company’s website at www.amagpharma.com. AMAG is a pharmaceutical company focused on bringing innovative products to patients with unmet medical needs.
AMAG Pharmaceuticals, Inc. (AMAG) today announced it has completed the sale of its rights to Intrarosa® (prasterone) to Millicent Pharma Limited, a global pharmaceutical company formed by the Millicent Pharma management team and The Carlyle Group in 2018 that specializes in women’s health and menopause-related conditions, for up to $125 million, including upfront fixed consideration of $20 million and contingent, sales-based milestone payments of up to $105 million. “As mentioned in our first quarter earnings release, the sale of Intrarosa is an important step in our strategic evolution,” said Scott Myers AMAG’s president and chief executive officer.
At this time I would like to welcome everyone to the AMAG Pharmaceuticals First Quarter 2020 Earnings Call. Good morning and welcome to the AMAG Pharmaceuticals conference call to discuss our first quarter 2020 financial results. Please be reminded that remarks made during this call may include forward-looking statements pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995.